Brokerages Set Omnicell, Inc. (NASDAQ:OMCL) Target Price at $59.86

Shares of Omnicell, Inc. (NASDAQ:OMCL) have earned a consensus recommendation of “Buy” from the nine research firms that are presently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a hold recommendation, seven have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price target among analysts that have covered the stock in the last year is $59.8571.

Several research firms have weighed in on OMCL. Craig Hallum reiterated a “buy” rating and issued a $55.00 target price on shares of Omnicell in a report on Wednesday, April 29th. Zacks Research upgraded shares of Omnicell from a “hold” rating to a “strong-buy” rating in a report on Friday, May 1st. Weiss Ratings upgraded shares of Omnicell from a “sell (d)” rating to a “hold (c-)” rating in a report on Thursday, May 7th. Wells Fargo & Company raised their price objective on shares of Omnicell from $52.00 to $55.00 and gave the stock an “overweight” rating in a report on Thursday, April 23rd. Finally, Wall Street Zen upgraded shares of Omnicell from a “buy” rating to a “strong-buy” rating in a report on Sunday, May 10th.

Omnicell Trading Up 0.0%

Shares of NASDAQ OMCL opened at $37.83 on Friday. The company’s 50 day simple moving average is $40.43 and its 200 day simple moving average is $41.48. Omnicell has a fifty-two week low of $26.84 and a fifty-two week high of $55.00. The firm has a market capitalization of $1.72 billion, a P/E ratio of 85.98, a P/E/G ratio of 0.98 and a beta of 0.97. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.50 and a quick ratio of 1.29.

Omnicell (NASDAQ:OMCL) last announced its quarterly earnings data on Tuesday, April 28th. The company reported $0.55 earnings per share for the quarter, beating the consensus estimate of $0.33 by $0.22. Omnicell had a net margin of 1.67% and a return on equity of 4.00%. The business had revenue of $309.88 million for the quarter, compared to analyst estimates of $304.02 million. During the same period in the prior year, the business posted $0.26 earnings per share. Omnicell’s revenue was up 14.9% compared to the same quarter last year. Omnicell has set its FY 2026 guidance at 1.800-2.000 EPS and its Q2 2026 guidance at 0.400-48.000 EPS. On average, analysts predict that Omnicell will post 1.31 EPS for the current year.

Insiders Place Their Bets

In related news, EVP Corey J. Manley sold 5,025 shares of the firm’s stock in a transaction on Monday, May 18th. The shares were sold at an average price of $43.22, for a total value of $217,180.50. Following the completion of the transaction, the executive vice president owned 112,783 shares of the company’s stock, valued at approximately $4,874,481.26. This trade represents a 4.27% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, EVP Nnamdi Njoku sold 3,090 shares of the firm’s stock in a transaction on Monday, May 18th. The shares were sold at an average price of $43.22, for a total transaction of $133,549.80. Following the completion of the transaction, the executive vice president directly owned 154,785 shares of the company’s stock, valued at approximately $6,689,807.70. This trade represents a 1.96% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders have sold 15,520 shares of company stock worth $607,610. 2.92% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Dimensional Fund Advisors LP increased its stake in shares of Omnicell by 6.0% during the 1st quarter. Dimensional Fund Advisors LP now owns 2,450,385 shares of the company’s stock worth $81,791,000 after purchasing an additional 137,834 shares during the last quarter. Wellington Management Group LLP increased its stake in shares of Omnicell by 156.4% during the 4th quarter. Wellington Management Group LLP now owns 2,075,362 shares of the company’s stock worth $94,014,000 after purchasing an additional 1,265,818 shares during the last quarter. Lazard Asset Management LLC increased its stake in shares of Omnicell by 3.8% during the 2nd quarter. Lazard Asset Management LLC now owns 1,708,345 shares of the company’s stock worth $50,225,000 after purchasing an additional 62,733 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. increased its stake in shares of Omnicell by 2.0% during the 1st quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,410,865 shares of the company’s stock worth $47,095,000 after purchasing an additional 27,497 shares during the last quarter. Finally, Geode Capital Management LLC increased its stake in shares of Omnicell by 1.0% during the 4th quarter. Geode Capital Management LLC now owns 1,127,583 shares of the company’s stock worth $51,088,000 after purchasing an additional 11,424 shares during the last quarter. Institutional investors own 97.70% of the company’s stock.

About Omnicell

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.